Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novartis Ag ADR
(NY:
NVS
)
102.57
-0.12 (-0.12%)
Official Closing Price
Updated: 7:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novartis Ag ADR
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
26
27
Next >
Novartis Says Relapsing Multiple Sclerosis Patients Remained Free From Disease Progression For Up Five Years With Kesimpta Treatment
April 20, 2023
Via
Benzinga
Why Shares of Legend Biotech Jumped Wednesday
April 19, 2023
A leaked abstract on a phase 3 trial for the company's multiple myeloma drug Carvykti gave the stock a jolt.
Via
The Motley Fool
New York Rep. Daniel Goldman Bought Over $50K Worth of Novartis Stock: Here's What You Should Know
April 18, 2023
Via
Benzinga
2 Best Biotech Stocks to Buy for the Long Haul
April 17, 2023
These two are among the largest pharma companies in the world.
Via
The Motley Fool
7 Sorry Pharma Stocks to Sell in April Before It’s Too Late
April 16, 2023
You have to be patient when investing in pharma stocks. But sometimes the risk and the wait aren't worth the rewards.
Via
InvestorPlace
Relay Therapeutics' Stock Price Premium Vs Peers Is Justified By Its Platform Technology, Analyst Says
April 13, 2023
Via
Benzinga
Novartis Earnings Conference Call Is Coming Up, Here's What You Need To Know
April 13, 2023
Via
Benzinga
FDA Approves Pharming's Immune Disorder Drug, As First APDS Therapy
March 27, 2023
Via
Benzinga
How Is The Market Feeling About Novartis?
March 21, 2023
Via
Benzinga
Alzheimer's Disease Largely Remains A Mystery, With A Lack Of Highly Effective Treatments — Could Regulatory T-Cells (Tregs) Be The Answer?
April 13, 2023
In many ways, Alzheimer's disease (AD) remains a mystery. Most common in those over 65, AD is the most common form of dementia, but its exact causes remain unclear, and treatments are unable to halt or...
Via
Benzinga
Trillions In Biotech Stock Gains Trace Back To This Financier
April 13, 2023
Frank did not grow up as son of a Wall Street banker. He began as the consummate outsider.
Via
Investor's Business Daily
Emergent BioSolutions Soars: Analyst Upgrades Stock With Near 100% Upside After FDA's Positive Move
April 10, 2023
Via
Benzinga
Top-Notch Biotech TG Therapeutics Logs 'Solid Jump' In Sales; Shares Rocket
April 10, 2023
Shares are closing in on a buy point out of a consolidation.
Via
Investor's Business Daily
Cryoport Supports Clinical Trials And Commercial Therapies Across The High-Growth BioTech Industry: Is Its Current Stock Price An Opportunity?
April 10, 2023
The global biotechnology industry was worth $859 billion in 2022, and it is predicted to reach $1.6 trillion by 2030, growing at a compound annual growth rate (CAGR) of 8.7% over the forecast period.
Via
Benzinga
FDA Approves Novartis' Tafinlar + Mekinist For Pediatric Brain Cancer With Certain Mutations
March 17, 2023
Via
Benzinga
6 Questions With Rocket Pharma's CEO On World Health Day: How The Biotech Is 'Changing The Narrative'
April 07, 2023
Rocket Pharma (NASDAQ: RCKT) CEO Gaurav Shah is on a mission to "change the narrative" when it comes to rare diseases.
Via
Benzinga
7 Very Undervalued Penny Stocks to Buy in April 2023
April 06, 2023
Undervalued penny stocks present investors who are very bullish on the near-term future with a high-risk, high-reward option.
Via
InvestorPlace
The Byzantine Adderall Shortage Puts Teva And Others In The Hot Seat
April 05, 2023
Millions of people are scrambling to get their ADHD medication. Here's why.
Via
Investor's Business Daily
Stock Market Rallies On Micron, Alibaba, Lululemon, Ebbing Bank Fears: Weekly Review
March 31, 2023
The stock market rallied on ebbing bank fears and positive news from Micron, Alibaba and Lululemon Athletica.
Via
Investor's Business Daily
What Bear Market? These 2 Winning Stocks Are Still Worth Buying.
March 30, 2023
These two pharma stocks are rock-solid picks in any kind of market.
Via
The Motley Fool
Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 27, 2023
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 59.6% to $0.2513. Crown Electrokinetics said it has entered into an agreement with a leading infrastructure solutions provider.
Via
Benzinga
Elon Musk-Led Neuralink Seeks Human Trial Collaborators, Credit Suisse May Face Disciplinary Action, First Citizens Takeover Silicon Valley Bank: Today's Top Stories
March 27, 2023
Benzinga
Via
Benzinga
Novartis Surges As It Goes After Eli Lilly's Second Biggest Moneymaker
March 27, 2023
The battle in early-stage breast cancer is heating up as Novartis enters the ring.
Via
Investor's Business Daily
Why Novartis Shares Are Trading Higher Premarket Today
March 27, 2023
Novartis AG (NYSE: NVS) shares are trading higher in the premarket session after its breast cancer drug showed clinical benefit in early-stage breast cancer.
Via
Benzinga
First Republic Bank, KeyCorp And Other Big Stocks Moving Higher In Monday's Pre-Market Session
March 27, 2023
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
2 Biotech Stocks That Could Make You Richer
March 21, 2023
One is a well-established, large-cap drugmaker, while the other is still making a name for itself in the industry.
Via
The Motley Fool
Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo
March 20, 2023
Two big-name partners have walked away from partnerships with Sangamo Therapeutics Inc (NASDAQ: SGMO) over a few days.
Via
Benzinga
Novartis Reveals Long-Term Data Of Atrophy Gene Therapy Exhibiting Sustained Durability Of Up To 7.5 Years
March 20, 2023
Via
Benzinga
Elon Musk Frets As Microsoft Axes AI Ethics Team, Richard Branson's Virgin Orbit Stops Ops, Credit Suisse To Borrow Up To $54B: Today's Top Stories
March 16, 2023
Benzinga
Via
Benzinga
Novartis' Prostate Cancer Therapy Hit By Supply Crunch, Seeks To Ramp Up Production To Ease Supply Issues
March 16, 2023
Last week the FDA said Novartis AG's (NYSE: NVS) Pluvicto is short in supply due to manufacturing and delivery issues. Pluvicto is a radiopharmaceutical medication used for prostate-specific membrane...
Via
Benzinga
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
26
27
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.